Empagliflozin: A Review in Type 2 Diabetes

Initiation of dapagliflozin and treatment-emergent fractures

(2018) Konstantinos A. Toulis et al.   DIABETES OBESITY & METABOLISM

Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents

(2018) David R. Saxon et al.   DRUGS

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY

(2018) Alan J. Garber et al.   Endocrine Practice

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

(2018) Hussein Al Jobori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

(2018) Mikhail Kosiborod et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

(2018) David Z.I. Cherney et al.   KIDNEY INTERNATIONAL

Does lower limb amputation concern all SGLT2 inhibitors?

(2018) André J. Scheen   Nature Reviews Endocrinology

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

(2017) Michael Fralick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease

(2017) Subodh Verma et al.   CIRCULATION

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

(2017) Christoph Wanner et al.   CIRCULATION

Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm

(2016) John P.H. Wilding et al.   DIABETES CARE

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

(2016) Eirik Søfteland et al.   DIABETES CARE

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes

(2016) Avivit Cahn et al.   DIABETES CARE

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

(2016) Huilin Tang et al.   DIABETES CARE

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

(2016) Muhammad Abdul-Ghani et al.   DIABETES CARE

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials

(2016) A. Salsali et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

(2016) F. Zaccardi et al.   DIABETES OBESITY & METABOLISM

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

(2016) David Cherney et al.   DIABETOLOGIA

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

The EMPA-REG study: What has it told us? A diabetologist’s perspective

(2016) Ralph A. DeFronzo   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost Effectiveness of Empagliflozin in Patients with T2DM and High CV Risk in Canada

(2016) SR Mettam et al.   VALUE IN HEALTH

Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data

(2016) I Daacke et al.   VALUE IN HEALTH

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

(2016) Deepson S Shyangdan et al.   BMJ Open

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

(2015) Michael Roden et al.   Cardiovascular Diabetology

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

(2015) Ian J Neeland et al.   Diabetes & Vascular Disease Research

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

(2015) Julio Rosenstock et al.   DIABETES CARE

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

(2015) R. Chilton et al.   DIABETES OBESITY & METABOLISM

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

(2015) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

(2015) Hans-Ulrich Haering et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Empagliflozin as add-on to metformin in people with Type 2 diabetes

(2015) L. Merker et al.   DIABETIC MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials 艾格列净治疗2型糖尿病：基于3期试验的安全性与有效性概述

(2015) George Dailey   Journal of Diabetes

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

(2014) Matthew M. Riggs et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

(2014) Ilkka Tikkanen et al.   DIABETES CARE

Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

(2014) Lesley J. Scott   DRUGS

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers

(2014) Lin-Zhi Chen et al.   XENOBIOTICA

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus

(2014) Daniel Lorber   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Impact of Diabetes on Cardiovascular Disease: An Update

(2013) Alessandra Saldanha de Mattos Matheus et al.   International Journal of Hypertension